FAMILIAL MELANOMA — CDKN2A

Familial Melanoma — CDKN2A loss-of-function carrying 60-90% lifetime melanoma risk and elevated pancreatic cancer risk, frequently dismissed as a family cancer cluster rather than recognized as a hereditary syndrome.

Whole genome sequencing reads the complete CDKN2A gene — which encodes two distinct tumor suppressors (p16/INK4a and p14/ARF) through alternative reading frames — identifying all variants including the rearrangements that standard panel sequencing misses.

CDKN2A

About this condition

Familial Melanoma — CDKN2A

Familial atypical multiple mole and melanoma syndrome (FAMMM) is an autosomal dominant hereditary cancer predisposition syndrome caused most commonly by germline pathogenic variants in CDKN2A on chromosome 9p21.3. CDKN2A encodes two distinct tumor suppressor proteins through alternative reading frames: p16/INK4a (encoded by exons 1α, 2, and 3), which inhibits CDK4/6 and prevents cell cycle progression, and p14/ARF (encoded by exons 1β, 2, and 3), which stabilizes p53. Pathogenic variants in CDKN2A account for approximately 20-40% of families with 3 or more melanoma cases and are present in a significant fraction of individuals with multiple primary melanomas. CDK4 pathogenic variants cause a nearly identical clinical syndrome in a minority of familial melanoma cases.

Lifetime melanoma risk in CDKN2A pathogenic variant carriers ranges from approximately 28-67% in low-incidence regions to 58-92% in high UV-exposure regions (notably Australia). Median age of first melanoma diagnosis in CDKN2A carriers is significantly younger than the general population, with a high rate of multiple primary melanomas throughout the carrier's lifetime. CDKN2A carriers also face substantially elevated pancreatic cancer risk — estimated at 11-17% lifetime — particularly when a family history of pancreatic cancer is present. Carriers with p14/ARF-specific variants (affecting only exon 1β) may have isolated pancreatic cancer predisposition without melanoma risk.

Despite the dramatic lifetime melanoma risk, familial melanoma is substantially underdiagnosed. Primary care and dermatology practices frequently encounter patients with multiple first-degree relatives with melanoma who are counseled about 'bad family luck' or simply given generic sun protection advice without referral for germline testing. NCCN melanoma guidelines recommend genetic evaluation for individuals with three or more invasive melanomas in a single family, multiple primary melanomas in one individual, or a family with one or more melanoma plus one pancreatic cancer. Confirmed CDKN2A carriers require annual full-body skin examination, semi-annual dermatoscopy, and pancreatic surveillance — a structured protocol that requires molecular confirmation to implement.

CDKN2A encodes two proteins through alternative reading frames. Exon 1β variants affect only p14/ARF, causing pancreatic cancer predisposition without melanoma risk. Exon 1α and exon 2-3 variants affect p16/INK4a and typically cause both melanoma and pancreatic cancer risk.

Gene locus: CDKN2A (9p21.3)

Standard melanoma panels use limited CDKN2A sequencing approaches that miss large rearrangements and alternative reading frame variants. Whole genome sequencing resolves the complete CDKN2A structure including both p16/INK4a and p14/ARF reading frames.

Two proteins, two reading frames — standard exon sequencing may not evaluate both correctly

CDKN2A is unusual in encoding two tumor suppressor proteins from a single genomic locus through alternative first exons: exon 1α (for p16/INK4a) and exon 1β (for p14/ARF). Standard hereditary cancer panels typically sequence CDKN2A coding exons in the p16/INK4a reading frame. Variants that specifically affect the p14/ARF reading frame — particularly in exon 1β — may be missed if the panel design does not explicitly cover this alternative first exon. Such variants confer pancreatic cancer predisposition that may be missed on a melanoma-focused panel design. Whole genome sequencing covers the complete 9p21 CDKN2A locus including both alternative first exons and the complete regulatory region.

Pancreatic cancer risk in CDKN2A families requires dedicated surveillance that standard melanoma follow-up does not include

CDKN2A carriers identified through a melanoma-presenting family may not be counseled about their concurrent 11-17% pancreatic cancer risk without explicit awareness of this dual phenotype. Current guidelines for CDKN2A carriers with a family history consistent with pancreatic cancer risk recommend annual pancreatic surveillance beginning at age 40-45 by endoscopic ultrasound or MRI/MRCP — the same surveillance recommended for BRCA2 and ATM pancreatic cancer risk carriers. This pancreatic surveillance protocol is initiated only when the CDKN2A diagnosis is established and the clinical team is aware of the dual cancer risk. Whole genome sequencing identifies CDKN2A pathogenic variants in the context of a comprehensive cancer risk assessment.

Familial Melanoma — CDKN2A loss-of-function carrying 60-90% lifetime melanoma risk and elevated pancreatic cancer risk, frequently dismissed as a family cancer cluster rather than recognized as a hereditary syndrome.

Familial Melanoma — CDKN2A

Standard melanoma panels use limited CDKN2A sequencing approaches that miss large rearrangements and alternative reading frame variants. Whole genome sequencing resolves the complete CDKN2A structure including both p16/INK4a and p14/ARF reading frames.

Two proteins, two reading frames — standard exon sequencing may not evaluate both correctly

Pancreatic cancer risk in CDKN2A families requires dedicated surveillance that standard melanoma follow-up does not include

Others in Hereditary Cancer

One test. A lifetime of answers.